Conference Proceedings

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

William G Wierda, John F Seymour, Andrew W Roberts, Su Young Kim, Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsenand Stephan Stilgenbauer

BLOOD | AMER SOC HEMATOLOGY | Published : 2017

Grants

Funding Acknowledgements

Emergent: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Kite: Research Funding; The University of Texas MD Anderson Cancer Center: Employment; Merck: Consultancy, Honoraria; Genentech/Roche: Consultancy, Honoraria, Research Funding; Janssen: Research Funding; GSK/Novartis: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Karyopharm: Research Funding; Genzyme: Consultancy, Honoraria; Acerta: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Juno: Research Funding; Gilead: Consultancy, Honoraria, Research Funding. Roberts: AbbVie: Other: Employee of Walter and Eliza Hall Institute of Medical Research which receives milestone and royalty payments related to venetoclax, Research Funding; Genentech: Research Funding; Amgen: Research Funding; BeiGene: Research Funding; Servier: Research Funding. Kim: AbbVie: Employment, Equity Ownership. LashFleming: AbbVie: Employment, Equity Ownership. Maher: AbbVie: Employment, Equity Ownership. Busman: AbbVie: Employment, Equity Ownership. Zhou: Abbvie: Employment, Equity Ownership. Nielsen: AbbVie Inc.: Employment, Equity Ownership. Stilgenbauer: Genentech: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; Hoffman La-Roche: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Mundipharma: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Genzyme: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Research Funding.